

10/584829
USPTO Rec'd PCT/PTO 27 JUN 2006
Attorney Docket No. 44342.025000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: ASAHI, Tetsuo, et al.

SERIAL NO.: TBA Art Unit: TBA

FILED: June 26, 2006 EXAMINER: TBA

FOR: AMIDE DERIVATIVE AND MEDICINE

United States Patent and Trademark Office
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants wish to bring co-owned U.S. Patent Application Publication No. US 2006/0014742 A1 to the Examiner's attention. That application generically discloses compounds which are similar to the compounds generically disclosed in the instant application.

Applicants also respectfully direct the Examiner's attention to Table 3 of the instant application. The values listed on Table 3 of the instant application are different from the values in Table 3 of the priority PCT application or the priority Japanese application. That is because the laboratory results listed in Table 3 were re-performed and the different, more accurate data obtained is presented in the instant application. Also, the more accurate data was reported by applicants in two publications: S. Kimura, et. al.; Blood, Vol. 106, No. 12, 3948-3954 (Dec. 1, 2005); and T. Asaki, et. al., 16 Bioorganic & Medicinal Chemistry Letters 1421-1425 (2006). Copies of these references are enclosed.

JAP20 Rec'd PCT/PTO 27 JUN 2006

Applicants also enclosed herewith the following references which were cited in the IDS:

WO 02/22597 A1; R. Parise, et. al., 791, J. Chromatography B 39-44 (2003); EP O 564 409 A1; and WO 2004/14903 A1. As for the IDS cited reference WO 2004/002963 A1, its U.S. counterpart is US 2006/0014742 A1. The U.S. counterpart is enclosed.

In addition, applicants include copies of the following references which are cited in the present specification: B.J. Druker, et. al., N. Engl. J. Med., Vol. 344, No. 14, 1038-1042 (April 5, 2001); M. Gorre, et. al., Science, Vol. 293, 876-880 (August 3, 2001); M.V. Blagosklonny, 16 Leukemia 570-572 (2002); A. Hochhaus, et. al., 16 Leukemia 2190-2196 (2002); W.K. Hofmann, et.al., Blood, Vol. 99, No. 5, 1860-1862 (March 1, 2002); and M. Deininger, et. al., Blood, Vol. 96, No. 10, 3343-3356 (November 15, 2000).

Finally, applicants enclose herewith a completed Form 1449.

Applicants do not believe that a fee is due because of the filing of this Information Disclosure Statement. If a fee is due, however, please deduct that fee from our Account No. 50-1561.

Dated: June 26, 2006

By: Respectfully submitted,



Gerard F. Diebner
Registration No. 31,345
Customer Number: 32361
Greenberg Traurig, LLP
200 Park Avenue
New York, NY 10166

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	TBA 10/584829
		Filing Date	June 26, 2005
		First Named Inventor	ASAKI, Tetsuo
		Art Unit	TBA
		Examiner Name	TBA
Sheet 2	of 2	Attorney Docket Number 44342.025000	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		S. KIMURA, et. al., NS-187, a Potent and Selective Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor, is a Novel Agent for Imatinib-Resistant Leukemia, Blood, Vol. 16, No. 12, 3948-3954 (December 1, 2005)		
		T. ASAKI, et. al., Design and Synthesis of 3-substituted Benzamide Derivatives as Bcr-Abl Kinase Inhibitors, 16 Bioorganic & Medicinal Chemistry Letters 1421-1425 (2006)		
		R. PARISE, et. al., Liquid Chromatographic - Mass Spectrometric Assay for Quantitation of Imatinib and its Main Metabolite (CGP 74588) in Plasma, 791 J. Chromatography B 39-44 (2003)		
		B. DRUKER, et. al., Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crises of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome, N. Engl. J. Med., Vol. 344, No. 14, 1038-1042 (April 5, 2001)		
		M. GORRE, et. al., Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation and Amplification, Science, Vol. 293 876-880 (August 3, 2001)		
		MV BLAGOSKLONNY, STI-571 Must Select for Drug-Resistant Cells but 'No Cell Breathes Fire Out of its Nostrils Like a Dragon', 16 Leukemia 570-572 (2002)		
		A. HOCHHAUS, et. al., Molecular and Chromosomal Mechanisms of Resistance to Imatinib (STI 1571) Therapy, 16 Leukemia 2190-2196 (2002)		
		W.K. HOFMANN, et. al., Ph+ Acute Lymphoblastic Leukemia Resistant to the Tyrosine Kinase Inhibitor STI 1571 has a Unique BCR-ABL Gene Mutation, Blood, Vol. 99, No. 5 1860-1862 (March 1, 2002)		
		M. DEININGER, et. al., The Molecular Biology of Chronic Myeloid Leukemia, Blood, Vol. 96, No. 10 3343-3356 (November 15, 2000)		

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.